DiaMedica Therapeutics (DMAC) is expected to complete enrollment for an interim futility analysis of its phase 2/3 ReMEDy2 clinical trial, using DM199 for the treatment of patients with acute ischemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback